Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advancis provides additional data for drug approval
In February 2007, Advancis received a “refusal to file” letter from the FDA for its once-daily Amoxicillin PULSYS new drug application. In its letter, the FDA indicated that
In February 2007, Advancis received a “refusal to file” letter from the FDA for its once-daily Amoxicillin PULSYS new drug application. In its letter, the FDA indicated that
Interleukin 6 (IL-6) is a crucial cytokine involved in the onset and progression of inflammatory diseases such as rheumatoid arthritis and cachexia. Based on in silico drug design,
The eye drug TG100801, applied daily in eye drop form, is designed to suppress disease related edema, angiogenesis and inflammation simultaneously. Currently approved therapies for macular degeneration require
“The results suggest that Albuferon may offer comparable or improved efficacy versus Pegasys, with half the injections and the potential for less impairment of health-related quality of life,”
Humira is also indicated for reducing the signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to
In two separate phase III studies, fluticasone furoate nasal spray (FFNS) was more effective than placebo in relieving both the nasal and eye symptoms of patients 12 years
According to the study, relief of symptoms occurred in all treated attacks after 1.3 hours in the mean after receiving C1-inhibitor (C1-INH) concentrate. In all untreated attacks, the
The phase II trial will examine Davanat with Avastin, 5-Fluorouracil (5-FU) and Leucovorin in patients with locally advanced, unresectable or metastatic colorectal cancer and unable to tolerate intensive
This phase I study is designed to evaluate the safety and pharmacokinetic properties of the inhibitor PA-040 in humans after a single dose. Maturation inhibition is a new
Difimicin was the subject of a joint development and collaboration agreement between the two companies in May 2005. Optimer will continue to develop Difimicin, which is expected to